sorafenib has been researched along with ovalbumin in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ovalbumin) | Trials (ovalbumin) | Recent Studies (post-2010) (ovalbumin) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 19,565 | 63 | 5,664 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bandukwala, H; Belsúe, V; Casares, N; Coffer, PJ; Durántez, M; Gorraiz, M; Hervás-Stubbs, S; Lasarte, JJ; Lourenço, AR; Lozano, T; Oyarzábal, J; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P; Villanueva, L | 1 |
1 other study(ies) available for sorafenib and ovalbumin
Article | Year |
---|---|
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Topics: Animals; Antineoplastic Agents; CD40 Ligand; Cell Proliferation; CTLA-4 Antigen; Female; Forkhead Transcription Factors; Humans; Immunotherapy; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Interleukin-6; Jurkat Cells; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; NFATC Transcription Factors; Niacinamide; Ovalbumin; Peptide Fragments; Phenylurea Compounds; Promoter Regions, Genetic; Receptors, Antigen, T-Cell; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2015 |